Actively Recruiting
Topical GHK-Cu Gel for Acute Skin Wound Healing
Led by Hudson Biotech · Updated on 2026-02-27
60
Participants Needed
1
Research Sites
110 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will evaluate whether a topical gel containing GHK-Cu (a copper(II)-peptide complex) can safely speed up healing of small, standardized skin wounds in healthy adults compared with a matching vehicle gel. Participants will receive two small punch-biopsy wounds on the upper arm; each wound will be randomly assigned to receive GHK-Cu gel or vehicle gel under identical dressings. Wounds will be photographed and assessed over 3 weeks, with a follow-up visit to evaluate scar quality.
CONDITIONS
Official Title
Topical GHK-Cu Gel for Acute Skin Wound Healing
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 55 years at screening.
- Healthy adult as determined by medical history and limited physical examination.
- Body mass index (BMI) between 18.0 and 30.0 kg/m².
- Willing and able to comply with study visits and daily application of study product for 14 days.
- Willing to avoid using non-study topical products on the wound area during the study.
- For participants of childbearing potential: negative pregnancy test at screening and agreement to use effective contraception through Day 21.
You will not qualify if you...
- Known allergy or sensitivity to copper, peptides, gel ingredients, adhesives, or dressings used in the study.
- History of abnormal wound healing, hypertrophic scars, or keloid formation.
- Significant skin conditions near the wound site such as eczema, psoriasis, or active infection.
- Diabetes, peripheral vascular disease, immunodeficiency, or other conditions impairing wound healing.
- Use of systemic corticosteroids, immunosuppressants, or cytotoxic drugs within 30 days before Day 0.
- Current smoker or nicotine use, including vaping, within the past 3 months.
- Pregnant or breastfeeding.
- Participation in another interventional clinical study within 30 days before screening.
- Any condition that may make participation unsafe or interfere with study assessments, as judged by the investigator.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China, 518036
Actively Recruiting
Research Team
S
Seni S Lu, Phd
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here